STOCK TITAN

IMMUNIC (IMUX) director receives 25,370 stock options at $14.80 strike price

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

IMMUNIC, INC. director Joerg Neermann received a grant of stock options covering 25,370 shares of common stock. The options have an exercise price of $14.80 per share and expire on July 5, 2036. They vest in monthly increments over one year from the grant date.

Positive

  • None.

Negative

  • None.
Insider Neermann Joerg
Role null
Type Security Shares Price Value
Grant/Award Stock Option 25,370 $0.00 --
Holdings After Transaction: Stock Option — 25,370 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 25,370 options Stock option grant to director on July 5, 2026
Exercise price $14.80 per share Strike price for IMMUNIC common stock under the option
Expiration date July 5, 2036 Option term end date
Underlying shares 25,370 shares IMMUNIC common stock underlying the option grant
Vesting schedule Monthly over one year From the grant date per footnote
Stock Option financial
"security_title: "Stock Option" with underlying IMMUNIC common stock"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion_or_exercise_price: "14.8000" per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-07-05T00:00:00.000Z" for the option grant"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
vests in monthly increments financial
"The option vests in monthly increments over a period of one year"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did IMMUNIC (IMUX) report for Joerg Neermann?

IMMUNIC reported that director Joerg Neermann received a grant of 25,370 stock options. These options give him the right to buy IMMUNIC common shares at a fixed exercise price, aligning part of his compensation with the company’s future stock performance.

What is the exercise price of Joerg Neermann’s new IMMUNIC (IMUX) stock options?

The granted stock options have an exercise price of $14.80 per share. This means Neermann can buy IMMUNIC common stock at $14.80, regardless of future market price, once the options vest and before they expire on July 5, 2036.

How many IMMUNIC (IMUX) shares are covered by Joerg Neermann’s option grant?

The option award covers 25,370 underlying shares of IMMUNIC common stock. Each option corresponds to one share, giving Neermann potential future equity exposure if he chooses to exercise the options after they vest and while they remain outstanding.

When do Joerg Neermann’s IMMUNIC (IMUX) stock options vest?

The stock options vest in monthly increments over one year from the grant date. This structure gradually delivers exercisable options each month, encouraging continued board service and tying Neermann’s potential equity benefits to his ongoing role with IMMUNIC.

What is the expiration date of Joerg Neermann’s IMMUNIC (IMUX) stock options?

The options expire on July 5, 2036. Neermann must exercise any vested options before that expiration date to acquire IMMUNIC common shares; unexercised options after that date will lapse and no longer be exercisable.

Is Joerg Neermann’s IMMUNIC (IMUX) option grant an open-market purchase or sale?

The filing classifies this as a grant or award acquisition, not an open-market trade. Neermann received the options from IMMUNIC as compensation, with no reported cash purchase or sale of shares on the market associated with this grant.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Neermann Joerg

(Last)(First)(Middle)
1200 AVENUE OF THE AMERICAS, SUITE 200

(Street)
NEW YORK NEW YORK 10036

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
IMMUNIC, INC. [ IMUX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option$14.807/05/2026A25,370 (1)07/05/2036Common Stock25,370$0.0025,370D
Explanation of Responses:
1. The option vests in monthly increments over a period of one year from the grant date.
/s/ Joerg Neermann07/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)